Alnylam Pharmaceuticals Inc Stock Price, News & Analysis

Alnylam Pharmaceuticals (Nasdaq: ALNY) reported positive interim data from its Phase 1 study of ALN-AGT, an RNAi therapeutic targeting angiotensinogen for hypertension treatment. Presented at the AHA Scientific Sessions 2020, data from 60 patients revealed significant AGT knockdown of up to 97.6% and considerable systolic and diastolic blood pressure reductions at 200 mg doses. The treatment demonstrated a favorable safety profile, with mild, transient adverse events observed. These results suggest a potential for innovative hypertension management with infrequent dosing, addressing the unmet need for improved patient adherence.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announces virtual presentations at two upcoming conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is scheduled for November 9, 2020, at 12:30 pm ET, followed by the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:00 pm ET. Investors can access a live audio webcast of each presentation on Alnylam's website, with replays available within 48 hours post-event. Alnylam is a leader in RNA interference therapeutics, focused on innovative medicines for rare genetic and other severe diseases.

Alnylam Pharmaceuticals (Nasdaq: ALNY) will announce its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before the U.S. markets open. The management team will host a conference call at 8:30 am ET on the same day to discuss the results and future expectations. Interested parties can access the call through a dedicated phone line or via a live audio webcast on the company's website. Alnylam focuses on RNA interference therapeutics aimed at treating various severe diseases with a robust product pipeline.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive 6-month results from the ILLUMINATE-B Phase 3 study of lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1 (PH1). The study showed a 72% mean reduction in urinary oxalate levels among children under six. Lumasiran's safety profile was assessed as acceptable, with no severe adverse events reported. Lumasiran is also under FDA review, with a decision expected by December 3, 2020. If approved, it will be marketed as OXLUMO in the EU, following a Positive Opinion from the EMA's CHMP.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a positive opinion from the European Medicines Agency's CHMP for lumasiran, an RNAi therapeutic targeting the HAO1 mRNA for treating primary hyperoxaluria type 1 (PH1). PH1 is a rare disease affecting 3.5 to 4 individuals per million, characterized by excessive oxalate production leading to severe kidney damage. If approved by the European Commission, lumasiran will be marketed as OXLUMO™. Clinical trials indicate significant reductions in urinary and plasma oxalate levels, demonstrating a promising safety profile.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive topline results from the ILLUMINATE-B Phase 3 study of lumasiran, an investigational RNAi therapeutic for primary hyperoxaluria type 1 (PH1). This trial is significant as it is the first assessing the safety and efficacy of lumasiran in children under six, including infants. The study enrolled 18 young patients and reported a clinically meaningful reduction in urinary oxalate levels. Lumasiran has received various FDA and EMA designations and a New Drug Application is pending with the FDA, set for review by December 3, 2020.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 4:15 PM ET. The company's management will provide a comprehensive overview during this event. A live audio webcast will be available on the Investors section of Alnylam's website, with a replay accessible within 48 hours post-presentation. Alnylam is at the forefront of RNA interference therapeutics, committed to innovating treatments for genetic and other serious diseases.